Literature DB >> 15297622

Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.

Ronald J Messer1, Ulf Dittmer, Karin E Peterson, Kim J Hasenkrug.   

Abstract

The current experiments use the Friend retrovirus model to demonstrate that vaccine-primed B cells are essential for sterilizing immunity, and the results indicate that the requisite function of these cells is the production of virus-neutralizing antibodies rather than priming or reactivation of T cells. B cell-deficient mice were poorly protected by vaccination, but adoptive transfer experiments showed that the T cells from B cell-deficient mice were primed as well as those from wild-type mice. Furthermore, passive transfer of virus-neutralizing antibodies completely compensated for B cell deficiency. The presence of virus-neutralizing antibodies at the time of infection was crucial for vaccine efficacy. Interestingly, virus-neutralizing antibodies worked synergistically with vaccine-primed T cells to provide a level of protection many orders of magnitude greater than either antibodies or immune T cells alone. Nonneutralizing antibodies also contributed to protection and acted cooperatively with neutralizing antibodies to reduce infection levels. These results emphasize the importance of inducing both T cell responses and virus-neutralizing antibody responses for effective retroviral vaccine protection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297622      PMCID: PMC514466          DOI: 10.1073/pnas.0404769101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  73 in total

1.  Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers.

Authors:  G Ferrari; W Humphrey; M J McElrath; J L Excler; A M Duliege; M L Clements; L C Corey; D P Bolognesi; K J Weinhold
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

2.  Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors.

Authors:  W Chen; H Qin; B Chesebro; M A Cheever
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

4.  Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness.

Authors:  K J Hasenkrug; D M Brooks; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

5.  Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells.

Authors:  M Iwashiro; T Kondo; T Shimizu; H Yamagishi; K Takahashi; Y Matsubayashi; T Masuda; A Otaka; N Fujii; A Ishimoto
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

6.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS.

Authors:  J Embretson; M Zupancic; J L Ribas; A Burke; P Racz; K Tenner-Racz; A T Haase
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

7.  Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques.

Authors:  T W Baba; Y S Jeong; D Pennick; R Bronson; M F Greene; R M Ruprecht
Journal:  Science       Date:  1995-03-24       Impact factor: 47.728

8.  Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting.

Authors:  M N Robertson; M Miyazawa; S Mori; B Caughey; L H Evans; S F Hayes; B Chesebro
Journal:  J Virol Methods       Date:  1991-10       Impact factor: 2.014

9.  Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein.

Authors:  O Schwartz; V Maréchal; S Le Gall; F Lemonnier; J M Heard
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

10.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.

Authors:  J P Moore; Y Cao; L Qing; Q J Sattentau; J Pyati; R Koduri; J Robinson; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

View more
  30 in total

1.  Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.

Authors:  Laurent Gros; Hanna Dreja; Anne Laure Fiser; Marc Plays; Mireia Pelegrin; Marc Piechaczyk
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

2.  Simian immunodeficiency virus SIVmac239 infection of major histocompatibility complex-identical cynomolgus macaques from Mauritius.

Authors:  Roger W Wiseman; Jason A Wojcechowskyj; Justin M Greene; Alex J Blasky; Tobias Gopon; Taeko Soma; Thomas C Friedrich; Shelby L O'Connor; David H O'Connor
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

3.  Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia.

Authors:  David Cervi; Yuval Shaked; Mehran Haeri; Tatiana Usenko; Christina R Lee; Jody J Haigh; Andras Nagy; Robert S Kerbel; Eitan Yefenof; Yaacov Ben-David
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

4.  Elimination of friend retrovirus in the absence of CD8+ T cells.

Authors:  Sachiyo Tsuji-Kawahara; Masaaki Miyazawa
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

5.  CD8+ and CD20+ lymphocytes cooperate to control acute simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys: modulation by major histocompatibility complex genotype.

Authors:  Hanwen Mao; Bernard A P Lafont; Tatsuhiko Igarashi; Yoshiaki Nishimura; Charlie Brown; Vanessa Hirsch; Alicia Buckler-White; Reza Sadjadpour; Malcolm A Martin
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  Persistence of viremia and production of neutralizing antibodies differentially regulated by polymorphic APOBEC3 and BAFF-R loci in friend virus-infected mice.

Authors:  Sachiyo Tsuji-Kawahara; Tomomi Chikaishi; Eri Takeda; Maiko Kato; Saori Kinoshita; Eiji Kajiwara; Shiki Takamura; Masaaki Miyazawa
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

7.  Myd88 is required for an antibody response to retroviral infection.

Authors:  Edward P Browne; Dan R Littman
Journal:  PLoS Pathog       Date:  2009-02-13       Impact factor: 6.823

8.  Complement as an endogenous adjuvant for dendritic cell-mediated induction of retrovirus-specific CTLs.

Authors:  Zoltán Bánki; Wilfried Posch; Asim Ejaz; Verena Oberhauser; Suzanne Willey; Christoph Gassner; Heribert Stoiber; Ulf Dittmer; Manfred P Dierich; Kim J Hasenkrug; Doris Wilflingseder
Journal:  PLoS Pathog       Date:  2010-04-29       Impact factor: 6.823

9.  Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo.

Authors:  Eri Takeda; Sachiyo Tsuji-Kawahara; Mayumi Sakamoto; Marc-André Langlois; Michael S Neuberger; Cristina Rada; Masaaki Miyazawa
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

Review 10.  Humoral immunity in the Friend retrovirus infection model.

Authors:  Kalani Halemano; Michael S Harper; Kejun Guo; Sam X Li; Karl J Heilman; Bradley S Barrett; Mario L Santiago
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.